205 results about "Treatment sleep" patented technology

Methods and / or devices to deliver pulmonary therapy to treat sleep disordered breathing are disclosed.

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composite sleep-aiding composition based on agilawood and a preparation method thereof. The preparation method comprises the following steps: carrying out ultrasonic-assisted enzymolysis on agilawood by adopting amylase and cellulase, carrying out mixed fermentation on the agilawood subjected to enzymolysis by inoculating lactobacillus plantarum, lactobacillus johnsonii and saccharomyces cerevisiae, and carrying out sterilization, filtration, concentration and drying treatment on the fermented agilawood to obtain the agilawood fermentation product. According to the method, the release rate of active substances in the agilawood is increased, the composite sleep-aiding composition containing the agilawood fermentation product has a remarkable sleep-aiding effect, the preparation method is simple, the problem that an existing agilawood product is poor in sleep treatment effect is solved, and the agilawood fermentation product is safe, free of irritation and high in application value.

A method of identifying a patient with obstructive sleep apnea implants a phrenic nerve stimulator in the patient or connects the phrenic nerve stimulator to the diaphragm, and adjusts the stimulation energy applied by the phrenic nerve stimulator to the phrenic nerve of the sleeping patient based on airway occlusion in the airway of the patient.

Devices and / or methods for treating sleep disordered breathing may include stimulation of a single nerve, multiple nerves, as well as other tissues relating to upper airway patency.

The invention provides a composition for treating sleep disorder, a preparation and a preparation method thereof. The composition comprises spina date seeds, poria with hostwood, cooked pseudo-ginseng, astragalus membranaceus, codonopsis pilosula and fried hawthorn. The traditional Chinese medicine composition is suitable for the technical field of traditional Chinese medicine preparations and can solve the problem of lack of traditional Chinese medicine compositions for improving sleep disorders caused by blood deficiency in the prior art.

A patient interface for treating sleep disorder breathing includes a textile tube that also provides support for the seal forming structure. The textile tube includes an inner and outer layer that are joined along seams to form an air chamber or passageway. The textile tube can be pre-shaped so that the textile tube resiliently returns to a pre-determined shape prior to the introduction of pressurized air.

Improved systems, methods, and devices for treating sleep apnea are provided herein. In one aspect, an intraoral appliance for treating sleep apnea in a patient comprises an appliance shell comprising a plurality of cavities shaped to receive teeth of a jaw of the patient. The appliance shell can comprise an advancement structure arranged to interact with an opposing jaw of the patient so as to displace the lower jaw anteriorly relative to the upper jaw. The plurality of cavities can comprise cavity geometries shaped to reduce repositioning of one or more received teeth elicited by displacement of the lower jaw anteriorly relative to the upper jaw.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Techniques for addressing sleep disorders are provided. A system includes a nerve stimulator that is configured to deliver stimulation energy to a nerve of a sleeping patient. A system includes a sensor for gather data from the sleeping patient and a controller for processing the data. The controller is configured to cause the stimulation energy that is provided to be adjusted based on the sensed data.

A medical device is provided that can be used to determine the optimal parameters for the detection of respiratory activity and the best modality for the modulation of the nervous system and / or respiratory muscles in response. Related systems and algorithms for programming the device, as well as the design parameters, are provided.

The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.

A device includes at least one first element in operative relation to at least one target tissue from a set of target tissues to treat sleep disordered breathing, which may include obstructive sleep apnea. The operative relation may include sensing and / or stimulation. The at least one target tissue may comprise diaphragm-related tissue, respiratory tissue-related nerves, and / or upper airway patency-related tissue. Example tissue in the set of target tissues includes hypoglossal nerve, infrahyoid muscle (IHM)-innervating nerve, IHMs, glossopharyngeal nerve, an internal superior laryngeal (iSL) nerve, phrenic nerve, diaphragm, pudendal nerve, among other nerves and muscles. In some example, multiple target tissue may be selected for stimulation and / or sensing.

The disclosure provides systems and methods for treating obstructive sleep apnea using an inertial measurement unit (IMU) comprising an accelerometer and a gyroscope, wherein the IMU is configured to detect chest and / or abdominal movement by a patient during the inspiration and expiration stages of a respiratory cycle and to generate positional data based on the detected movement. Positional data generated by the IMU is used by an implanted stimulation system to determine when to deliver electrical stimulation to a nerve which innervates an upper airway muscle, such as the hypoglossal nerve, to treat sleep apnea.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided are systems, methods, and devices for providing mediation or alleviation of sleep disorders and insomnia. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with sleeping disorders and insomnia. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the sleeping disorder or insomnia. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

To provide oral appliances that can be used to treat sleep apnea syndrome (SAS) ranging from mild to severe. [Solution] One embodiment of an oral appliance for sleep apnea is an oral appliance that is fitted into the user's oral cavity. The oral appliance comprises an upper jaw portion, a lower jaw portion, and a drive unit. The upper jaw portion has a shape that mimics the user's upper teeth and contacts the upper teeth. The lower jaw portion has a shape that mimics the user's lower teeth and contacts the lower teeth. The drive unit connects the upper jaw portion and the lower jaw portion so as to be able to change the relative position of the lower jaw portion with respect to the upper jaw portion, and drives the lower jaw portion. The drive unit has a control circuit that determines whether the user is in a state of apnea based on sensor information obtained from a sensor that detects the user's apnea state, and if the user is in a state of apnea, drives the lower jaw portion toward the user's forward position, and if the user is not in a state of apnea, drives the lower jaw portion to return to the user's resting position.

An oral appliance may include a mouthpiece configured to be positioned in an oral cavity of a user and an electronic assembly coupled to the mouthpiece. The electronic assembly may include an oxygen sensor oriented toward soft tissue of the user's mouth to determine an oxygen saturation level of the user. The electronic assembly may be positioned within an appendage extending away from a wall of the mouthpiece.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition containing zolpidem tartrate and trazodone hydrochloride as well as a preparation and application of the composition, the trazodone hydrochloride can treat sleep disorders under the condition of single use and can remarkably treat the sleep disorders when being combined with zolpidem tartrate, and pharmacological experiments find that the trazodone hydrochloride can be used for treating the sleep disorders. The sleep latency can be remarkably shortened and the sleep time can be prolonged by combined medication; the content of 5HT and NE in blood is improved.

A system for determining parameters for implantable devices that are designed to electrically stimulate the phrenic nerve to treat sleep disordered breathing is provided. The system may use techniques to automate the identification of the parameters that are needed for the recognition and classification of the input signals as well as their values. The system may use techniques for the optimization of the electrical stimulation therapy that is delivered by the implantable device.

The present specification is directed a method manufacturing a patient interface for treatment of sleep disordered breathing using air pressure by delivery of air to a patient's airway. The method includes locating a shell, a first sub section of a seal forming structure, and a first section of the seal forming structure in a tool. The first sub section includes a groove. The first section is constructed from a thermoformable material. The method further includes introducing a moulding material to the tool and overmolding the shell, the first sub section, and the first section. The moulded material forms a second sub section of the seal forming structure that connects the first sub section to the shell and fully encloses the first section within the groove.

Techniques for automated titration of CPAP device for a subject include receiving multiple ultrasound images representing a cross section of an airway in a neck of the subject at corresponding different times. Multiple different positive pressure values imposed by a device on the airway of the subject are also received at each of the corresponding times. For each of the ultrasound images, a mask of pixels associated with an air-tissue interface is automatically formed, and a value of a statistic of pixels within the mask is automatically determined. A titration pressure for a continuous positive airway pressure (CPAP) device is automatically determined based on the positive pressures and the value of the statistic for each of the ultrasound images. Output data that indicates the titration pressure for the CPAP device is presented on a display device, such as by operating the CPAP device itself at the titration pressure.

Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burst or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form Methods of making and using the compositions are also provided.

The invention discloses an application of a CHRNA3 agonist in treatment of sleep disorders. The application finds that the CHRNA3 agonist varenicline can effectively relieve the sleep disorder reaction for the first time, on this basis, the invention provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder, and meanwhile, provides a method for screening candidate drugs for treating diseases caused by hypoxia stress, and provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder. A new treatment means is provided for sleep disorder, especially sleep disorder caused by hypoxia stress.

A device (100) for treating sleep apnea or other breathing disorders is provided. The device (100) comprises an upper portion (101), a lower portion (102), and an intermediate portion (103). The upper portion (101) is configured to be placed on at least one tooth of the upper jaw of a patient, and the lower portion (102) is configured to be placed on at least one tooth of the lower jaw of the patient. The intermediate portion (103) is configured to couple the upper and lower portions (101, 102) together to maintain a fixed position of the upper and lower jaws when placed on the teeth of the upper and lower jaws of the patient. The device (100) further comprises at least one fastening member, such as floss, nitinol wire, rubber band or the like. The fastening member is configured to engage at least one interdental space of each of the upper and lower jaws to fasten the upper and lower portions (101, 102) to the teeth of the upper and lower jaws, respectively. The device of the present invention, thus, provides an improved oral appliance for treating sleep apnea, specifically obstructive sleep apnea, that is able to maintain the upper and lower jaws of the patient in a fixed position to keep the airway open.

The invention relates to a cerebroprotein peptide and casein hydrolysate composition and application thereof in improving sleep and memory, and belongs to the technical field of biological protein peptides. According to the preparation method disclosed by the invention, Maillard modification of the casein enzymolysis primary product is realized by screening the enzymolysis protease of the bovine milk casein and screening the carbonyl compound which is subjected to Maillard reaction with the casein enzymolysis primary product, so that the reducing power, the metal ion chelating capacity and the antioxidant capacity of the casein hydrolysate are effectively improved; furthermore, free radicals in the body are removed, oxidative stress reaction is relieved, and a good foundation is laid for improving sleep quality. The brain protein peptide and the casein hydrolysate are compounded, so that the sleep latency can be effectively shortened, the sleep rate can be increased, the sleep can be effectively improved, the content of dopamine and noradrenaline in hypothalamus can be reduced, the content of 5-hydroxytryptamine and the content of aminobutanoin can be increased, and the brain protein peptide composition has good effects of relieving and treating sleep disorders and improving memory.

Disclosed are heat and moisture exchangers for use in treatment of sleep disordered breathing. In some examples the heat and moisture exchangers may be positioned within the plenum chamber of a patient interface, an air circuit connected to the patient interface or within a conduit of a positioning and stabilising structure. In examples the heat and moisture exchanger is configured to provide a pressure drop of less than 5 cm of H2O, when measured at a flow rate of 100 litres per minute, while maintaining a humidity level of inhaled air which is 10 mg / L or greater.

The present technology generally relates to methods for addressing sleep apnea in a patient. At least some of the methods may include one or more of percutaneously inserting an implantable signal delivery device at an insertion point on a patient's neck, moving the signal delivery device in a medial-to-lateral direction toward a neck loop nerve of the patient, and implanting the signal delivery device at a target location at least proximate the neck loop nerve. The signal delivery device may include at least one electrode positioned to deliver a modulation signal to tissue, such as a portion of a neck loop nerve, at least proximate to a target location. In some embodiments, delivery of the modulation signal may induce a patient's trailing-side traction, thereby addressing sleep apnea in the patient.

The present disclosure relates to a composition for preventing, ameliorating or treating sleep disorder or insomnia, which contains an extract of a roasted citrus byproduct as an active ingredient. The extract of a roasted citrus byproduct of the present disclosure has very excellent effect of decreasing sleep latency, increasing sleep duration and increasing non-REM sleep. In addition, the composition of the present disclosure, which contains ingredients derived from the naturally occurring citrus byproduct, can ensure safety without inducing the side effects of synthetic drugs including pentobarbital and benzodiazepine and with no side effects such as cognitive impairment, tolerance or dependency even after long-term use. Accordingly, the composition for preventing, alleviating or treating sleep disorder, which contains an extract of a roasted citrus byproduct as an active ingredient, of the present disclosure is very useful for preparation of a food composition and a pharmaceutical composition.